Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
FDA has now determined that the inspection classification of this facility is “official action indicated” (OAI).
For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025.
Suraksha Diagnostic Ltd lost 7.95% today to trade at Rs 294.5. The BSE Healthcare index is down 0.51% to quote at 47612.76. The index is up 9.48 % over last one month. Among the other constituents of the index, Max Healthcare Institute Ltd decreased 5.18% and Aurobindo Pharma Ltd lost 3.54% on the day. The BSE Healthcare index went up 11.99 % over last one year compared to the 7.03% fall in benchmark SENSEX.
Suraksha Diagnostic Ltd has added 4.27% over last one month compared to 9.48% gain in BSE Healthcare index and 4.15% drop in the SENSEX. On the BSE, 1019 shares were traded in the counter so far compared with average daily volumes of 3298 shares in the past one month. The stock hit a record high of Rs 353.65 on 26 Jun 2025. The stock hit a 52-week low of Rs 224.1 on 30 Mar 2026.
Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1541.4, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 23630.9. The Sensex is at 75137.86, down 0.24%. Aurobindo Pharma Ltd has gained around 8.46% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 10.58% in last one month and is currently quoting at 24843.15, down 0.04% on the day. The volume in the stock stood at 4.58 lakh shares today, compared to the daily average of 12.95 lakh shares in last one month.
The benchmark May futures contract for the stock is quoting at Rs 1540, up 1.34% on the day. Aurobindo Pharma Ltd is up 29.73% in last one year as compared to a 3.98% slide in NIFTY and a 15.38% slide in the Nifty Pharma index.
The PE of the stock is 41.12 based on TTM earnings ending December 25.
Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1514.7, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.27% on the day, quoting at 23710.55. The Sensex is at 75385.46, up 1.04%. Aurobindo Pharma Ltd has risen around 10.25% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 9.11% in last one month and is currently quoting at 23896.05, up 2.44% on the day. The volume in the stock stood at 7.76 lakh shares today, compared to the daily average of 14.11 lakh shares in last one month.
The benchmark May futures contract for the stock is quoting at Rs 1522.1, up 1.16% on the day. Aurobindo Pharma Ltd is up 24.47% in last one year as compared to a 5.39% drop in NIFTY and a 13.06% drop in the Nifty Pharma index.
The PE of the stock is 40.57 based on TTM earnings ending December 25.
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from 28 January to 10 February 2026. At the end of the inspection, a ‘Form 483' was issued with a total of 9 observations.
The Unit has now received Establishment Inspection Report (EIR) classifying the facility as 'Voluntary Action Indicated' (VAI). FDA has concluded that this inspection is now closed.
Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1436.1, up 1.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Aurobindo Pharma Ltd has risen around 12.06% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 13.11 lakh shares today, compared to the daily average of 17.53 lakh shares in last one month.
The benchmark April futures contract for the stock is quoting at Rs 1436.1, up 1.33% on the day. Aurobindo Pharma Ltd is up 14.18% in last one year as compared to a 0.21% drop in NIFTY and a 4.48% drop in the Nifty Pharma index.
The PE of the stock is 38.5 based on TTM earnings ending December 25.
The approved formulation is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Delsym extended-release oral suspension, 30 mg/5 mL, marketed by RB Health (US) LLC.
Aurobindo Pharma said the product will be manufactured at Unit IV of APL Healthcare, its wholly owned subsidiary, and is expected to be launched in Q2 FY27.
According to Nielsen data for the 12 months ended February 2026, the product has an estimated market size of $138 million. With this approval, the company now has a total of 580 ANDA approvals from the USFDA, including 557 final approvals and 23 tentative approvals.
The official announcement was made on 17 April 2026, after market hours.
Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 7.6% rise in consolidated net profit to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.
The counter shed 0.62% to Rs 1,377 on the BSE.